Systematic review and meta-analysis of the efficacy of using CAR-T cells in patients with pancreatic cancer in reducing tumor size and improving overall survival rates
1M. El-Tara, 2A. Ahmed
1Elsadat STEM School, Sers Alliana City, Egypt
2Menofia STEM School, Ashmoun City, Egypt
Publication date: December 12, 2024
1Elsadat STEM School, Sers Alliana City, Egypt
2Menofia STEM School, Ashmoun City, Egypt
Publication date: December 12, 2024
ABSTRACT
This systematic review evaluates the effectiveness and safety of Chimeric Antigen Receptor T-cell (CAR-T) therapy in pancreatic cancer patients. The study aimed to assess the impact of CAR-T cell therapy on tumor size reduction and overall survival rates compared to standard treatments. Eligible studies were published between 2014 and 2024 and were analyzed using databases like PubMed, ClinicalTrials.gov, and IYRC. The pooled analysis showed a significant reduction in tumor size, with an average decrease of 72.30%. However, there was substantial heterogeneity, indicating variability in the results across different studies. Secondary outcomes such as overall survival rates and progression-free survival varied depending on the study design and patient characteristics. The evidence suggests that CAR-T cell therapy holds promise for reducing tumor size in pancreatic cancer patients, but the findings are tempered by small sample sizes, lack of randomized controlled trials, and variability in CAR-T cell therapy protocols.
This systematic review evaluates the effectiveness and safety of Chimeric Antigen Receptor T-cell (CAR-T) therapy in pancreatic cancer patients. The study aimed to assess the impact of CAR-T cell therapy on tumor size reduction and overall survival rates compared to standard treatments. Eligible studies were published between 2014 and 2024 and were analyzed using databases like PubMed, ClinicalTrials.gov, and IYRC. The pooled analysis showed a significant reduction in tumor size, with an average decrease of 72.30%. However, there was substantial heterogeneity, indicating variability in the results across different studies. Secondary outcomes such as overall survival rates and progression-free survival varied depending on the study design and patient characteristics. The evidence suggests that CAR-T cell therapy holds promise for reducing tumor size in pancreatic cancer patients, but the findings are tempered by small sample sizes, lack of randomized controlled trials, and variability in CAR-T cell therapy protocols.
